newsfilter
← Latest News
ACCESS Newswire·

Valion Bio's New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value

Interim CEO Dean Zikria's initial review prioritizes Entolimod and pipeline advancement, commercialization of Velocity Bioworks, and strategic opportunities to maximize the value of the Company's integrated